IBRX ImmunityBio, Inc. Net earnings per share growth this year

IBRX (ImmunityBio, Inc.) - company brandmark

ImmunityBio, Inc. (IBRX) develops cancer vaccines based on NK-cell activation. The year-over-year shift in EPS illustrates a transition toward the long-term monetization of unique patents. Business success is now dictated solely by clinical trial results, rendering demand inelastic. The value of -175.50 determines the current status of the earnings per share parameter relative to the previous year.

ImmunityBio (IBRX): Net earnings per share growth this year from 07/04/2022 to 11/10/2026

Analytical breakdowns and data insights for company ImmunityBio, Inc. (IBRX)

- current quotes and average value forecast:
Market Chart ImmunityBio Inc|IBRX - Price Target Chart
- market capitalization data:
Market Valuation NantKwest|IBRX - Total Company Value
- company book value details:
Accounting Value per Share ImmunityBio|IBRX - Company Net Assets|Market Capitalization to Book Value Ratio immunitybio.com|IBRX - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Ratio ImmunityBio, Inc.|IBRX - Long-Term Debt to Equity|Current Liabilities to Capital immunitybio.com|IBRX - Company Total Debt|Debt to Net Assets NantKwest|IBRX - Company Long-Term Liabilities|Amount of Current Liabilities ImmunityBio|Intermediate Coverage Ratio immunitybio.com
- net income and valuation ratios data:
IBRX - Net Profit|Expected Net Profit ImmunityBio, Inc.|IBRX - Price to Earnings Ratio|Future Price to Earnings Multiple NantKwest|IBRX - PEG Multiple|EV/EBITDA Multiple NantKwest|IBRX - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months ImmunityBio|IBRX - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months immunitybio.com|IBRX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year ImmunityBio, Inc.
Summary company analysis:IBRX (ImmunityBio Inc)
Brand item of ImmunityBio Corp

Assessing capital resilience to market shocks requires an analysis of net income per share growth rates relative to the previous year. For ImmunityBio, Inc. (IBRX), the launch of its proprietary IL-15 therapy establishes a foundation for growth, which the EPS YoY price action reflects through the percentage ratio of current to historical figures, confirming the effectiveness of innovation commercialization and the strengthening of the company's market position.

Key competitors

IMCR - Expected net earnings per share growth this year|Earnings per share growth in current year Janux Pharma|Net earnings per share growth this year Arcus Corp (RCUS)|Earnings per share growth in current year Zymeworks Inc. (ZYME)|Net earnings per share growth this year tangotx.com TNGX|Iovance Biotherapeutics, Inc. - Net earnings per share growth this year|Earnings growth in current year Immatics NV IMTX|XNCR - Earnings per share growth in current year|CMPX (Compass Therapeutics Corp) - Earnings per share growth this year|Replimune Group, Inc. (REPL) - Earnings per share growth in current year|Earnings per share growth rate in current year lyell.com (LYEL)|Net earnings per share growth this year IPHA|PYXS - Net earnings per share change in current year|Net earnings per share growth this year CGEN (Compugen Ltd.)|Net earnings per one share growth for the current year IOBT|Earnings growth in current year STRO (Sutro Biopharma, Inc.)|Earnings per share increase in current year INKT|Werewolf - Earnings growth in current year|Earnings per share growth rate in current year Immix Biopharma, Inc.|ALX Oncology (ALXO) - Earnings per share growth in current year|Cue Biopharma Inc. - Earnings per share increase in current year|PDSB (PDS Biotech) - Earnings growth in current year|Earnings growth in current year Sonnet BioTherapeutics Holdings Inc.|Earnings per share growth in current year MAIA Biotechnology, Inc. (MAIA)|LIMN: Earnings per share trend in current year|LAVA Therapeutics - Net earnings per share growth this year|NextCure Corporation (NXTC) - Earnings per share growth rate in current year|Leap Tx - Earnings growth in current year|Expected net earnings per share growth this year Intensity Therapeutics INTS|senseibio.com (SNSE) - Earnings per share growth in current year|Net earnings per share growth this year Theriva Biologics Inc|Earnings per share growth in current year Gritstone bio Inc.|Net earnings per share growth this year Kineta Corp (KA)|Net earnings per share growth this year NEXI (NexImmune, Inc.)|Earnings growth in current year turnstonebio.com (TSBX)|Earnings per share growth in current year Vaccinex VCNX|HARP: Earnings per share growth this year